Rayamajhee Binod, Willcox Mark, Henriquez Fiona L, Shrestha Gauri Sr, Yadav Uday Narayan, Fazal Amberin, Hong Sheng Chiong, Chorny Alexander, Asrat Yalewayker, Petsoglou Constantinos, Carnt Nicole
School of Optometry and Vision Science, Faculty of Medicine and Health, UNSW, Sydney, NSW, Australia.
School of Biological, Earth and Environmental Sciences (BEES), UNSW, Sydney, NSW, Australia.
IJID Reg. 2025 Jun 15;16:100690. doi: 10.1016/j.ijregi.2025.100690. eCollection 2025 Sep.
keratitis (AK) is an emerging corneal infection. This study evaluated the prevalence of AK, assessed circulating genotypes, and identified potential sources of infection.
A prospective case series study was conducted at the Sydney Eye Hospital, Australia, from June 2021 and October 2022. Corneal swabs from AK patients were collected for culture, and their domestic water samples were also analyzed. Cyst morphology, polymerase chain reaction, and Sanger sequencing were performed to confirm the isolates.
A total of 21 AK patients were recruited in this study (41 ± 12.3 years). Six (28.6%) corneal and four (44.4%) water samples tested positive for genotype T4. One corneal and one water isolate harbored intracellular bacteria, with the water isolate containing . Eight patients were contact lens wearers. Eye pain was the primary symptom (66.7%), followed by red eye. The median duration of symptoms was 24.5 days (interquartile range: 13-95 days). Polyhexamethylene biguanide was the main therapy, followed by chlorhexidine. The median treatment duration was 12 weeks (interquartile range: 8-26 weeks).
In Sydney, the prevalent genotype of among AK patients and tap water was T4. This study suggests a higher annual incidence of AK than previously reported.
棘阿米巴角膜炎（AK）是一种新出现的角膜感染。本研究评估了AK的患病率，分析了循环基因型，并确定了潜在的感染源。
2021年6月至2022年10月在澳大利亚悉尼眼科医院进行了一项前瞻性病例系列研究。收集AK患者的角膜拭子进行培养，并对其家庭用水样本进行分析。进行囊肿形态学、聚合酶链反应和桑格测序以确认分离株。
本研究共纳入21例AK患者（41±12.3岁）。6份（28.6%）角膜样本和4份（44.4%）水样的基因型T4检测呈阳性。1份角膜分离株和1份水分离株含有细胞内细菌，水分离株含有[此处原文缺失相关内容]。8例患者为隐形眼镜佩戴者。眼痛是主要症状（66.7%），其次是眼红。症状的中位持续时间为24.5天（四分位间距：13 - 95天）。聚六亚甲基双胍是主要治疗药物，其次是洗必泰。中位治疗持续时间为12周（四分位间距：8 - 26周）。
在悉尼，AK患者和自来水中棘阿米巴的流行基因型为T4。本研究提示AK的年发病率高于先前报道。
